



Identification of a novel carbamoyl glucuronide as a metabolism-dependent inhibitor of CYP2C8.

Faraz Kazmi¹, Brian Smith¹, Mette G. Hvenegaard², Lene Bendahl², Amy Gipson¹, David Buckley¹, Brian Ogilvie¹ and Andrew Parkinson¹ | ¹XenoTech, LLC, Lenexa KS, USA 66219, ²Department of Drug Metabolism, H. Lundbeck A/S, Copenhagen, Denmark
Presented at the 9th International ISSX Meeting, Istanbul, Turkey, September 2010
Poster 197, *Drug Metabolism Reviews*, Volume 42, Supplement 1, 2010

ABSTRACT

Glucuronidation is a major route of drug biotransformation and detoxification, whereby a drug is conjugated with glucuronic acid in a reaction catalyzed by UDP glucuronosyltransferases (UGTs). However, previous reports suggest glucuronide conjugates can be inhibitors of Phase I metabolism. Of particular note is gemfibrozil glucuronide, which is oxidized by CYP2C8, causing clinically relevant irreversible inactivation of this enzyme (Ogilvie *et al.*, 2006). In the present study, we evaluated the ability of Lu AA34893 and its carbamoyl glucuronide to inhibit *in vitro* the major drug metabolizing cytochrome P450 (CYP) enzymes. In NADPH-fortified human liver microsomes (HLM), Lu AA34893 was found to directly inhibit CYP2C19 (IC₅₀ = 0.20 μM), CYP2D6 (IC₅₀ = 6.9 μM), CYP3A4/5 (as measured by testosterone 6β-hydroxylation, IC₅₀ = 9.7 μM; midazolam 1'-hydroxylation, IC₅₀ = 15 μM; and nifedipine oxidation, IC₅₀ = 15 μM), CYP2A6 (IC₅₀ = 17 μM), CYP2B6 (IC₅₀ = 17 μM), CYP2C9 (IC₅₀ = 20 μM), CYP2C8 (IC₅₀ = 24 μM), and CYP1A2 (IC₅₀ = 54 μM). Furthermore, Lu AA34893 was found to competitively inhibit CYP2C19 and CYP3A4/5 (testosterone) with K_i values of 0.08 μM and 6.7 μM, respectively, and to act as a mixed inhibitor of CYP2D6 (K_i = 3.0 μM), and CYP3A4/5 (midazolam, K_i = 6.1 μM; nifedipine, K_i = 7.8 μM). Minimal metabolism-dependent inhibition (MDI) of several CYP enzymes by Lu AA34893 was observed. Assessment of the carbamoyl glucuronide of Lu AA34893, showed that, of the CYP enzymes evaluated, only CYP2C8 was inhibited directly (IC₅₀ = 71 μM). Of particular interest, when pre-incubated with NADPH-fortified human liver microsomes for 30 minutes prior to measurement of CYP activity, the carbamoyl glucuronide was found to be a MDI of CYP2C8, with over an 8-fold shift in IC₅₀ (IC₅₀ = 8.5 μM), unlike its aglycone. Additionally, there was some evidence of MDI of CYP2C19 (IC₅₀ shift from >100 μM to 66 μM). These findings demonstrate another example (*i.e.*, in addition to gemfibrozil) in which glucuronidation of a drug candidate converts the parent to a potent MDI of CYP2C8.



Reference:

Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson A (2006) Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: Implications for drug-drug interactions. *Drug Metab Dispos* **34**:191-197.

INTRODUCTION

Glucuronidation is a major pathway of Phase 2 biotransformation that expedites the elimination of drugs or their Phase 1 metabolites. The conjugation of drugs with glucuronic acid is catalyzed by multiple microsomal UDP-glucuronosyltransferase (UGT) enzymes. Although Phase 1 reactions (oxidation, reduction and hydrolysis) generally precede glucuronidation and other Phase 2 reactions, there is a growing list of drugs (such as gemfibrozil, diclofenac, 17 β -estradiol, naproxen, licoferone and the PPAR- α/γ agonist MRL-C) that undergo Phase 1 metabolism by CYP2C8 after they have undergone Phase 2 metabolism involving glucuronidation. In the case of gemfibrozil, CYP2C8 not only hydroxylates gemfibrozil glucuronide, but the enzyme becomes irreversibly inactivated due to heme alkylation (Ogilvie *et al.*, 2006; Baer *et al.*, 2009). The metabolism-dependent inactivation of CYP2C8 by gemfibrozil glucuronide is responsible, at least in part, for the pharmacokinetic and sometimes lethal interaction between gemfibrozil and cerivastatin (Baycol[®]), the cholesterol-lowering drug that was withdrawn from American, European and Japanese markets in 2001 (Backman *et al.*, 2002; Shitara *et al.*, 2004; Ogilvie *et al.*, 2006).

In the present study we describe a novel drug candidate conjugate, the carbamoyl glucuronide of Lu AA34893 that, like gemfibrozil glucuronide, functions as an irreversible metabolism-dependent inhibitor of CYP2C8. Lu AA34893 is a secondary amine (proprietary structure). Its conjugation with glucuronic acid likely involves the incorporation of carbon dioxide to form a carbamate, which is conjugated with glucuronic acid to form a carbamoyl glucuronide, as has been speculated for other amine-containing drugs like sertraline (Obach *et al.*, 2005):



The basic structure of Lu AA34893 carbamoyl glucuronide

MATERIALS & METHODS

Chemicals

Pooled human liver microsomes ($n=16$, mixed gender) were prepared and characterized at XenoTech, LLC (Lenexa, Kansas) as described previously (Pearce *et al.*, 1996; Parkinson *et al.*, 2004). Lu AA34893 and its carbamoyl glucuronide were provided by H. Lundbeck A/S (Copenhagen, Denmark). Potassium ferricyanide was purchased from Sigma-Aldrich (St. Louis, Missouri). The sources of the other reagents used in this study have been described elsewhere (Robertson *et al.*, 2000; Ogilvie *et al.*, 2006; Paris *et al.*, 2009).

In vitro CYP inhibition IC_{50} determinations

The ability of Lu AA34893 and its carbamoyl glucuronide to inhibit the major CYP enzymes in a direct and metabolism-dependent manner was investigated with pooled HLMs, as described by Ogilvie *et al.*, 2006, 2008 and Paris *et al.*, 2009. To assess direct inhibition, incubations were conducted at 37°C in incubation mixtures containing potassium phosphate buffer (50 mM, pH 7.4), $MgCl_2$ (3 mM), EDTA (1 mM, pH 7.4), an NADPH-generating system (consisting of 1 mM NADP, 5 mM glucose-6-phosphate and 1 Unit/ml glucose-6-phosphate dehydrogenase) and CYP marker substrate (*i.e.*, phenacetin, 40 μ M; coumarin, 0.75 μ M; bupropion, 50 μ M; paclitaxel, 10 μ M; diclofenac, 6 μ M; *S*-mephenytoin 40 μ M; dextromethorphan, 7.5 μ M; midazolam, 4 μ M; testosterone, 100 μ M; or nifedipine, 10 μ M), at the final concentrations indicated. Reactions were initiated by the addition of the NADPH-generating system and terminated after 5 min with an equal volume of acetonitrile (*v/v*) containing an appropriate internal standard.

To assess metabolism-dependent inhibition, Lu AA34893 or its carbamoyl glucuronide (0.1, 0.3, 1, 3, 10, 30 and 100 μ M) were preincubated at 37°C with NADPH-fortified pooled HLMs for 30 minutes. After the preincubation period, the marker substrate (at a concentration approximately

equal to its K_m) was added, and the incubation continued for 5 min to measure residual CYP activity. Reactions were terminated with an equal volume of acetonitrile containing an appropriate internal standard. Metabolite formation was determined by LC/MS/MS as described previously (Ogilvie *et al.*, 2008; Paris *et al.*, 2009).

Reversibility of CYP2C8 inhibition by Lu AA34893 carbamoyl glucuronide

The reversibility of the observed metabolism-dependent inhibition of CYP2C8 by Lu AA34893 carbamoyl glucuronide was assessed based on an ultracentrifugation method as described by Buckley *et al.*, 2008. Briefly, Lu AA34893 carbamoyl glucuronide was preincubated with HLM for 30 min in the presence and absence of NADPH. After the preincubation, HLMs were (a) re-isolated by ultracentrifugation and then assessed for residual CYP2C8 activity, or (b) treated with potassium ferricyanide, re-isolated by ultracentrifugation and then assayed for residual CYP2C8 activity.

The kinetics of CYP2C8 inactivation (K_i/k_{inact})

To determine the K_i and k_{inact} values for the inactivation of CYP2C8 by the carbamoyl glucuronide of Lu AA34893, preincubations were performed with NADPH-fortified pooled HLM at approximately 25 times the normal protein concentration (*i.e.*, 1.25 mg/mL for paclitaxel 6 α -hydroxylation) for zero, 3, 6, 9, 15 and 30 minutes. After the preincubation, an aliquot of the preincubation mixtures was transferred to a second tube containing the marker substrate, at approximately 2 times its K_m and an NADPH-generating system resulting in a 25-fold dilution. The incubation with marker substrate was continued for 5 min, after which residual CYP2C8 activity was measured as described above.

RESULTS

Table 1 summarizes IC_{50} values of Lu AA34893 and its carbamoyl glucuronide for direct and metabolism-dependent inhibition of CYP activity in HLM. The parent compound, Lu AA34893, caused direct inhibition of all CYP enzymes evaluated. It was an especially potent inhibitor of CYP2C19 (IC_{50} 0.2 μ M), although even the least potently inhibited enzyme (CYP1A2) was inhibited with an IC_{50} value of 54 μ M. Further evaluation of the most potently inhibited enzymes revealed that, as a direct inhibitor, Lu AA34893 competitively inhibits CYP2C19 and CYP3A4/5 (testosterone) with K_i values of 0.08 μ M and 6.7 μ M, respectively, and functioned as a mixed inhibitor of CYP2D6 ($K_i = 3.0$ μ M), and CYP3A4/5 ($K_i = 6.1$ μ M; nifedipine, $K_i = 7.8$ μ M) (data not shown).

In contrast to the parent compound, the carbamoyl glucuronide metabolite, when evaluated as a direct inhibitor, failed to inhibit any of the CYP enzymes evaluated with an IC_{50} value less than 100 μ M, with the exception of CYP2C8, which was inhibited with an IC_{50} value of 71 μ M. Furthermore, the carbamoyl glucuronide of Lu AA34893 caused metabolism-dependent inhibition of CYP2C8 with a greater than 8-fold shift in IC_{50} following a 30-min preincubation with NADPH-fortified HLM (from IC_{50} 71 μ M to 8.5 μ M), as shown in **Figure 1**. Furthermore, there was some evidence of modest metabolism-dependent inhibition of CYP2C19 by the carbamoyl metabolites (IC_{50} shift from >100 μ M to 66 μ M). However, there is some evidence that this inhibition of CYP2C19 may not be NADPH-dependent (data are not shown).

Figure 2 shows the results of an ultracentrifugation experiment designed to assess the reversibility of the metabolism-dependent inhibition of CYP2C8 by Lu AA34893 carbamoyl glucuronide. The metabolism-dependent inhibition of CYP2C8 by Lu AA34893 carbamoyl glucuronide was not reversed by isolating the HLM (which otherwise reverses the inhibition associated with the formation of a more potent, direct-acting inhibitor), nor was it reversed by treatment with potassium ferricyanide (which otherwise reverses the inhibition associated with formation of a metabolite inhibitor complex [MIC] due to coordination of a metabolite with the ferric heme iron). The results in **Figure 2** suggest that Lu AA34893 carbamoyl glucuronide is an irreversible inactivator of CYP2C8, as previously demonstrated for gemfibrozil glucuronide.

The kinetics of CYP2C8 inactivation by the carbamoyl glucuronide of Lu AA34893 were determined as described in **Materials & Methods**, and the results are shown in **Figure 3**. The carbamoyl glucuronide of Lu AA34893 inactivated CYP2C8 with a k_{inact} of 0.038 min^{-1} and a K_i of 48 μ M ($k_{inact}/K_i = 0.79$ $\text{min}^{-1} \text{mM}^{-1}$).

Table 1.

In vitro evaluation of Lu AA34893 and its carbamoyl glucuronide as inhibitors of CYP enzymes (IC₅₀ values)

Enzyme	Lu AA34893		Carbamoyl glucuronide of Lu AA34893	
	0-min Preincubation	30-min Preincubation	0-min Preincubation	30-min Preincubation
CYP1A2	54	56	>100	>100
CYP2A6	17	34	>100	>100
CYP2B6	17	13	>100	>100
CYP2C8	24	14	71	8.5
CYP2C9	20	15	>100	>100
CYP2C19	0.20	0.12	>100	66
CYP2D6	6.9	3.9	>100	>100
CYP3A4/5 (M)	15	8.8	>100	>100
CYP3A4/5 (T)	9.7	6.0	>100	>100
CYP3A4/5 (N)	15	8.9	>100	>100

M, T, N denote midazolam, testosterone and nifedipine, respectively

Note: IC₅₀ values in μM

Figure 1.

Comparison of CYP2C8 IC₅₀ plots between Lu AA34893 and its carbamoyl glucuronide





Figure 2.


Assessment of the reversibility of CYP2C8 inhibition by Lu AA34893 carbamoyl glucuronide



100 μM Lu AA34893 carbamoyl glucuronide	-	-	+	+	+
Solvent	+	+	+	+	+
NADPH	+	+	+	-	+
$\text{K}_3\text{Fe}(\text{CN})_6$	-	+	-	-	+
Re-isolated	+	+	+	+	+

Figure 3.

Determination of the kinetic parameters of inactivation for the carbamoyl glucuronide of Lu AA34893 with CYP2C8



CONCLUSIONS

- The secondary amine Lu AA34893 was a direct-acting inhibitor of all the CYP enzymes examined and was a potent inhibitor of several of them ($IC_{50} < 10 \mu M$). However, the parent compound caused little or no metabolism-dependent inhibition.
- In contrast to the parent compound, its carbamoyl glucuronide metabolite was a weak inhibitor of all the CYP enzymes examined (with IC_{50} values exceeding $100 \mu M$ in all but one case).
- In contrast to the parent compound, its carbamoyl glucuronide metabolite functioned as an irreversible metabolism-dependent inhibitor of CYP2C8 ($k_{inact} = 0.038 \text{ min}^{-1}$; $K_i = 48 \mu M$; $k_{inact}/K_i = 0.79 \text{ min}^{-1} \text{ mM}^{-1}$).

Lu AA34893 serves as another example, along with gemfibrozil, of a compound that is converted by glucuronidation to a conjugated metabolite that functions as an irreversible metabolism-dependent inhibitor of CYP2C8.

REFERENCES

Backman JT, Kyrklund C, Neuvonen M, and Neuvonen PJ (2002) Gemfibrozil greatly increases the plasma concentrations of cerivastatin. *Clin Pharmacol Ther* **72**:685-691.

Baer BR, DeLisle RK, Allen A (2009) Benzylic oxidation of gemfibrozil-1-O- β -glucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition. *Chem Res Toxicol* **22**:1298-1309.

Buckley D, Yerino P, Kazmi F, Scheinkoenig J, Ogilvie B, Paris B, and Parkinson A (2008) Metabolism-dependent cytochrome P450 inhibitors: *In vitro* assessment of reversibility by ultracentrifugation methods. *Drug Metabolism Reviews* **40**:Supplement 3, Abstract 237.

Obach RS, Cox LM, Tremaine LM (2005) Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronoyl transferases in human: An *in vitro* study. *Drug Metab Dispos* **33**:262-270.

Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P and Parkinson A (2006) Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: Implications for drug-drug interactions. *Drug Metab Dispos* **34**:191-197.

Ogilvie BW, Usuki E, Yerino P and Parkinson A (2008) *In vitro* approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs (Reaction Phenotyping) with emphasis on cytochrome P450, in: *Drug-Drug Interactions* (Rodrigues AD ed), pp 231-358, Informa Healthcare USA Inc., New York, NY.

Paris BL, Ogilvie BW, Scheinkoenig JA, Ndikum-Moffor F, Gibson R and Parkinson A (2009) *In vitro* inhibition and induction of human liver cytochrome P450 enzymes by milnacipran. *Drug Metab Dispos* **37**:2045-2054.

Parkinson A, Mudra DR, Johnson C, Dwyer A and Carroll KM (2004) The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. *Toxicol Appl Pharmacol* **199**:193-209.

Pearce RE, Rodrigues AD, Goldstein JA and Parkinson A (1996) Identification of the human P450 enzymes involved in lansoprazole metabolism. *J Pharmacol Exp Ther* **277**:805-816.

Shitara Y, Hirano M, Sato H and Sugiyama Y (2004) Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: Analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. *J Pharmacol Exp Ther* **311**:228-236.